Oncology A cancer treatment modality that prioritises QoL, with Ben Z... Immuneering's Ben Zeskind explains how, by focusing on quality of life as well as quantity, they've created a drug for pancreatic cancer.
Oncology Engineering “smarter” cells, with Tim Lu Senti Bio's Tim Lu discusses “logic-gated” cells, which have multiple receptors allowing them to attack cancer cells while leaving healthy cells alone
Oncology Astellas’ banner year and focused R&D strategy, with Adam Pe... At JPM2026, Astellas' chief strategy officer Adam Pearson walked pharmaphorum through the company’s four-pillared R&D strategy.
Oncology Unlocking the future of epigenetics, with Carlos Buesa Carlos Buesa, CEO of Oryzon Genomics, discusses exploring how epigenetics is reshaping the landscape of oncology and CNS therapies.
Oncology ESMO25: On radiopharmaceutical possibilities in oncology, wi... At ESMO 2025, pharmaphorum spoke with Dr Ebrahim Delpassand, CEO of RadioMedix.
Oncology ESMO25: On allosteric modulation in oncology, with Michael L... At ESMO 2025, pharmaphorum had the pleasure of speaking with Michael Lahn, Chief Medical Officer at iOnctura.
News Iran hackers claim cyberattack at US medtech firm Cyberattack by an Iranian group against Stryker points to a shift in strategy from extortive to destructive assaults, as geopolitical conflicts rise.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.